# \[e-drug\] Launch of the 2021 AMR Benchmark Report
**URL:** https://talk.edrugplus.org/t/e-drug-launch-of-the-2021-amr-benchmark-report/46651
**Category:** e-drug
**Created:** [November 23, 2021, 2:18pm UTC](https://talk.edrugplus.org/t/e-drug-launch-of-the-2021-amr-benchmark-report/46651 "2021-11-23T14:18:47Z")
**Posts on this page:** 1
**Page:** 1
### Author:  [@Fatema\_Rafiqi](https://talk.edrugplus.org/u/Fatema_Rafiqi)
#### Post date: [November 23, 2021, 2:18pm UTC](https://talk.edrugplus.org/t/e-drug-launch-of-the-2021-amr-benchmark-report/46651/1 "2021-11-23T14:18:47Z")
E-DRUG: Launch of the 2021 AMR Benchmark Report
------------------------------------------------------
Dear E-drug colleagues,
I'm emailing to inform you all that the 2021 Antimicrobial Benchmark Report
is now available and live on our website:
[https://accesstomedicinefoundation.org/amr-benchmark/2021-benchmark](https://accesstomedicinefoundation.org/amr-benchmark/2021-benchmark)
It is the result of nearly two years of methodology review, stakeholder
input, company input, data collection, analysis and writing. Thank you to
all who contributed!
I've included a high-level summary of the Benchmark in this mailing, and
the headlines of the key findings for this report. We look forward to your
responses and feedback. As with your work, our insights also work when they
are shared and discussed by those in global health.
The 2021 AMR Benchmark evaluates 17 companies with a major stake in the
anti-infectives space, including large research-based companies and generic
medicines manufacturers. By comparing how they perform across a set of 20
metrics and 3 research areas, the Benchmark tracks the progress and gaps in
their efforts to keep medicines and vaccines available, despite the rise of
drug resistance.
FEATURES:
- 17 Report Cards
- 11 Best Practices
- 3 Key Findings
- Insights and Trends in Industry Action on AMR
Good practice is becoming more common. Action to address access lags behind.
Good practice is becoming more common in the actions taken by
pharmaceutical companies to limit the threat of antimicrobial resistance
(AMR). This is most notable in the plans to ensure wider access to and
responsible use of future products, as well as in the steps taken to curb
the release of antibiotic waste into the environment. In stewardship,
generic medicine manufacturers are taking a more active role. However, all
companies miss opportunities to improve access in low- and middle-income
countries (LMICs), where the need is greatest and where people face the
greatest threat from superbug infections.
Key Findings
1. Increased access and stewardship planning in R&D is hopeful sign for
poorer countries
2. Progress on limiting release of antibiotic waste into environment,
but gaps remain
3. Pharma companies make limited use of the many ways to improve access
to antibiotics
Please check the new website that features an extended company report card
section, a comparison hub where you can directly compare company report
card sections. All results from our in-depth analysis can be filtered by
companies, topics, regions and pathogens. Best practices can be filtered by
companies, research areas and topics.
As always, we are more than happy to engage on all of our results, respond
to any questions, schedule meetings, etc.
Best wishes,
Fatema Rafiqi
Fatema H. Rafiqi, PhD
Research Programme Manager
Access to Medicine Foundation
Naritaweg 227-A, 1043 CB, Amsterdam
The Netherlands
www.accesstomedicinefoundation.org
Fatema Rafiqi \